Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT00482625 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

NIH

Sponsor class

Stopped The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug supply, IND closure).

Conditions

Intraductal Papillary Mucinous Neoplasm of the Pancreas
Recurrent Pancreatic Cancer
Stage IA Pancreatic Cancer
Stage IB Pancreatic Cancer
Stage IIA Pancreatic Cancer
Stage IIB Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions

DRUG: erlotinib hydrochloride
PROCEDURE: conventional surgery
OTHER: immunohistochemistry staining method
GENETIC: protein expression analysis
PROCEDURE: biopsy
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)